12 March 2020

Contents

Editorial

• HTB 12 March 2020 now online

• HTB survey 2020 – please help with feedback

Special reports

• Fit for purpose: antiretroviral treatment optimisation March 2020

• HIV pipeline 2020: new drugs in development – March 2020

Conference reports

• Conference on Retroviruses and Opportunistic Infections (CROI 2020)

• CROI 2020: Special session on COVID-19

• Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally

• Long-acting cabotegravir and rilpivirine injections support two-monthly dosing

• Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing

• First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance

• Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial

• Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women

• London patient is second person to be cured of HIV from allogeneic stem-cell transplant

• The London Patient tells his story as second person cured of HIV

Treatment access

• Dolutegravir/lamivudine FDC recommended by NHS England

PDFs

• 12 March 2020 vol 21 no 3